EMBOLEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Embolex, and what generic alternatives are available?
Embolex is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in EMBOLEX is dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. There are six drug master file entries for this compound. Additional details are available on the dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EMBOLEX?
- What are the global sales for EMBOLEX?
- What is Average Wholesale Price for EMBOLEX?
Summary for EMBOLEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 131 |
| Clinical Trials: | 1 |
| DailyMed Link: | EMBOLEX at DailyMed |
Recent Clinical Trials for EMBOLEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis | Phase 3 |
US Patents and Regulatory Information for EMBOLEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-001 | Nov 30, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-002 | Nov 30, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EMBOLEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-002 | Nov 30, 1984 | 4,451,458 | ⤷ Start Trial |
| Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-001 | Nov 30, 1984 | 4,402,949 | ⤷ Start Trial |
| Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-002 | Nov 30, 1984 | 4,402,949 | ⤷ Start Trial |
| Novartis | EMBOLEX | dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride | INJECTABLE;INJECTION | 018885-001 | Nov 30, 1984 | 4,451,458 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EMBOLEX
See the table below for patents covering EMBOLEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 371997 | ⤷ Start Trial | |
| Austria | A550480 | ⤷ Start Trial | |
| Australia | 535357 | ⤷ Start Trial | |
| Australia | 6426580 | ⤷ Start Trial | |
| Belgium | 886008 | ⤷ Start Trial | |
| Canada | 1165692 | SOLUTIONS STABLES D'ALCALOIDES D'ERGOT HYDROGENES (STABLE SOLUTIONS OF HYDROGENATED ERGOT ALKALOIDS) | ⤷ Start Trial |
| Switzerland | 650930 | STABILE LOESUNGEN VON HYDRIERTEN ERGOTALKALOIDEN BZW. IHREN SALZEN UND HEPARIN BZW. SEINEN SALZEN SOWIE VERFAHREN ZU DEREN HERSTELLUNG. | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch